Business Wire

LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years

Del

NOT FOR DISTRIBUTION IN THE UNITED STATES

LEO Pharma today announced new Phase III data broadening the evidence base for the efficacy, safety and quality of life benefits of Kyntheum ® (brodalumab), a biologic treatment for people with moderate-to-severe plaque psoriasis. Results from a long-term extension study found Kyntheum® provided sustained high levels of skin clearance (PASII 100) over more than two years in those with moderate-to-severe disease.1 Separate pooled analyses from the AMAGINE clinical trials showed that patients receiving Kyntheum® reported significant health-related quality of life improvements versus placebo.2,3 These data were presented at the 26th European Academy of Dermatology (EADV) annual congress in Geneva, Switzerland.

Psoriasis is a serious, lifelong condition impacting emotional, psychological and physical health. Although its systemic nature often remains unrecognised, people living with psoriasis are at an increased risk of developing serious associated conditions, which further impact quality of life.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.5 For these reasons, lasting skin clearance of symptoms and plaques is an important treatment goal, especially for those with the most severe forms of the disease.5

Results from the AMAGINE-2 extension study confirmed Kyntheum® was able to deliver completely clear skin (PASI 100) in more than half of patients (56.2%, n=779) and almost clear skin (PASI 90) in more than three-quarters of patients (76.8%, n= 779) after two years (120 weeks) of treatment.1 The proportions of patients achieving high levels of skin clearance were comparable to results at year one (week 52) (with 53% and 78% of patients achieving PASI 100 and PASI 90, in year one respectively).1 At week 120, Kyntheum® continued to be well-tolerated with a comparable safety profile, as observed in the 52-week study.1 The most common adverse events were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection, arthralgia (joint pain), and headache.1

“These new data are encouraging as they demonstrate the potential long-term efficacy and safety of Kyntheum ® and reinforce its ability to provide psoriasis patients with high levels of lasting skin clearance. It is important that people with moderate-to-severe plaque psoriasis have treatment options that help them to not only achieve clear, healthy skin, but also the capability to relieve the substantial burden the disease places on patients’ everyday lives,” commented Professor Dr. Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.

The burden of psoriasis on quality of life is comparable to other chronic conditions like diabetes and heart diseases.6 Measuring improvements in health-related quality of life is important as they reflect a patient’s experience or perception of disease impact, which is not evaluated by PASI scores alone.7

New pooled analyses of the Phase III AMAGINE(-1,-2,-3) studies showed that significantly greater improvements in health-related quality of life were experienced with Kyntheum® compared with placebo, as measured by the Dermatology Life Quality Index (DLQI)II questionnaire.2,3 At week 12, 59% of Kyntheum® patients reported psoriasis had no impact on their overall quality of life compared to 6% of patients on placebo.3 This was experienced specifically with significant improvements across daily/leisure activities, as well as work/school lives.2 Furthermore, at week 12, 43% of Kyntheum® patients were no longer embarrassed or self-conscious about their psoriasis.3

“Psoriasis is not just a skin condition and the full impact of the disease is often underestimated,” said Gitte Pugholm Aabo, President and CEO, LEO Pharma. “At LEO Pharma we are dedicated to supporting patients with innovative treatment solutions such as Kyntheum ® that can help patients live a more positive life, clear of their skin condition.”

Kyntheum® was granted marketing authorisation by the European Commission in July 20178 and is the first and only biologic that selectively targets the IL-17 receptor subunit A.9,10 By binding to this specific receptor on the cells of the skin, rather than targeting free inflammatory mediators, Kyntheum® blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are involved in psoriasis plaque formation.10,11,12 This mechanism of action is different to all other psoriasis biologics currently available.10,13

A total of 16 Kyntheum® abstracts are being presented at the 2017 EADV annual congress.

- ENDS-

NOTES TO EDITORS

About Kyntheum ®

Kyntheum® (brodalumab) is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A.10,13 By binding to the receptor with high affinity, Kyntheum® effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis.ý13,14

The psoriasis clinical studies programme for Kyntheum® consisted of three clinical trials; AMAGINE-1 (n=661), AMAGINE-2 (n=1831) and AMAGINE-3 (n=1881).15,16 Results showed Kyntheum® 210mg offered more patients complete skin clearance (PASI 100) at 12 weeks compared to patients treated with ustekinumab [AMAGINE-2: 44% (n=272) versus 22% (n=65), p<0.001; AMAGINE-3: 37% (n=229) versus 19% (n=58), p<0.001].15

In AMAGINE-1 83% of patients on Kyntheum® 210mg achieved PASI 75 compared to 3% of patients treated with placebo at 12 weeks [83.3% (n=185) versus 2.7% (n=6), p<0.001] and 76% of patients achieved sPGAIII success versus 1% of patients treated with placebo [75.7% (n=168) versus 1.4% (n=3), p<0.001].16

In the AMAGINE trials more than half (53-56%) of patients on continuous Kyntheum® treatment achieved PASI 100 at week 52.16,17

Patients also reported experiencing improved health-related quality of life after four weeks of treatment with Kyntheum®.18 After 12 weeks of treatment, seven in 10 patients (72%, n=29/40, p<0.0001) reported psoriasis no longer impaired their health-related quality of life, (0/1 DLQI) compared with placebo (5%, n=2/37).18

Data from the three large randomised, controlled AMAGINE clinical trials, found Kyntheum® to be well tolerated, with an acceptable safety profile.19 The most common adverse events were arthralgia (joint pain), headache, fatigue, diarrhoea and oropharyngeal (mouth and throat) pain.16

In July 2016, LEO Pharma entered into a partnership agreement with AstraZeneca granting LEO Pharma exclusive licence to develop and commercialise Kyntheum® in Europe.IV Outside of Europe, Valeant Pharmaceuticals has global commercial rights for brodalumab except in Japan and certain other Asian countries, where the rights are held by Kyowa Hakko Kirin Co. Ltd.

About psoriasis

Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.5 The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).5

An estimated 125 million people worldwide live with psoriasis,20 including nearly 14 million Europeans.21

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.22 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,4 including heart disease23,24,25 and metabolic diseases (a combination of diabetes, high blood pressure and obesity).26 Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.27

According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.5

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. LEO Pharma offers a comprehensive range of integrated care solutions for control and relief of psoriasis. By expanding its portfolio into biologics, through the approval of Kyntheum®, the company is set to become the world’s leading dermatology company.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit www.leo-pharma.com

Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal

Follow us on Twitter: www.twitter.com/leohealthyskin

Visit us at LinkedIn: www.linkedin.com/company/leo-pharma

I The Psoriasis Area and Severity Index (PASI) score is used in clinical trials to indicate a % change in disease, i.e. PASI 75 is defined as the proportion of patients that reach ≥ 75% improvement in Psoriasis Area and Severity Index score. PASI 90 or PASI 100 indicates patients who have achieved almost clear or complete skin clearance

II The Dermatology Life Quality Index (DLQI), is a tool commonly used by Dermatologists to assess the quality of life impact of skin disease across areas such as work and social activities as well as symptoms and patients’ feelings about their condition. The data presented at EADV refers to responses to specific sections of this overall DLQI questionnaire.

III sPGA success is defined as patients who achieved a static Physician’s Global Assessment 0 or 1

IV Kyntheum® is not approved by Swissmedic for marketing in Switzerland.

References

1. Lebwohl M, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1790

2. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1791

3. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1792

4. Reich K. Eur Acad Dermatol Venereol. 2012; 26(2):3-11

5. World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed September 2017)

6. Rapp SR, et al. J Am Acad Dermatol 1999;41:401-407

7. Grob JJ. J Invest Dermatol. 2007;127:2299-2301

8. European Medicines Agency, European public assessment report, Kyntheum® (brodalumab). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003959/human_med_002054.jsp&mid=WC0b01ac058001d124 (Accessed September 2017)

9. Kyntheum®. Summary of Product Characteristics. 2017

10. Campa M, et al. Dermatol Ther. 2016;6:1–12

11. Beringer A, et al. Trends Mol Med. 2016; 22: 230-41

12. Russell CB, et al. J Immunol. 2014; 192: 3828-36

13. Coimbra S, et al. Core Evidence. 2014;9:89-97

14. Papp K, et al. N Engl J Med 2012;336:1181-9

15. Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

16. Papp K, et al. Br J Dermatol. 2016;175:273–286

17. Supplement to: Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

18. Gordon KB, et al. Br J Dermatol. 2014;170:705–15

19. Attia A, et al. Clin Drug Investig. 2017; DOI: 10.1007/s40261-017-0500-9

20. The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed September 2017)

21. Ortonne J, et al. Eur J Dermatol. 2004;14:41–45

22. National Institute for Health and Care Excellence (NICE) Psoriasis: assessment and management guidelines. Available at: https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#systemic-therapy (Accessed September 2017)

23. Gelfand JM, et al. JAMA. 2016;296:1735-41

24. Ahlehoff O, et al. Eur Heart J. 2012;33:2054-64

25. Lowes MA, et al. Ann Rev Immunol. 2014;32:227-35

26. Langan SM, et al. J Invest Dermatol. 2012 Mar; 132(3 0 1): 556–562

27. Dalgard F, et al. JID. 2015;135(4), 984-991

Contact information

LEO Pharma
Global media contacts
Henrik Steen Heskjær Kyndlev
Head of Global External Communication
Email: HDTDK@leo-pharma.com
Mobile: +45 3140 6180
or
Marie Schleimann Nordlund
Snr Global Patient Communication Manager
Email: marie.nordlund@leo-pharma.com
Mobile: +45 3126 3734

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Triaconta Announces a New Safe Way to Invest in Cryptocurrencies21.9.2017 16:18Pressemelding

Triaconta wants to minimize the risks of investing in cryptocurrencies with Combicoin to make the cryptocurrency market accessible for a larger audience. CombiCoin is 100% asset backed by the top 30 cryptocurrencies with the highest market cap. Because of this the CombiCoin will not suddenly plunge and investors will have less risks when there are major fluctuations. There are over 1000 cryptocurrencies on the market and together they represent a value of 130 billion USD. However, all these coins are very volatile. For example, the value of bitcoin grew from 1000 to 4000 USD within six months. The value of Ethereum, the second largest cryptocurrency, rose from 150 to 400 USD within 6 months but plunged to 150 USD 4 weeks later. In the first six months of 2017 the top 30 of cryptocurrencies grew with 1200 percent. The value of CombiCoin is determined for 3.3

TIP Trailer Services Announces the Successful Refinancing of its ABS program21.9.2017 15:16Pressemelding

On 21 September 2017, TIP Trailer Services announced that it had successfully refinanced its Asset Backed Securitisation (ABS) program. The Pan-European program was originally established in 2014 and is a securitisation structure common under Dutch law for operating leases. The new program will run until March 2019. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005815/en/ At the official signing of the TIP ABS refinancing were: From left to right: Jorrit Achterberg (Legal Counsel, TIP Trailer Services), Patrick Vergouwen (International Investor Relations Manager, TIP Trailer Services), Bart de Boo (Director, Asset Based Finance, Rabobank), Gert Huizing (Quality Assurance Manager Capital Market Services, Intertrust), Leo van der Sman (Legal Counsel, Intertrust) (Photo: Business Wire) “The extra funding and improved co

Tohatsu, Major Outboard Manufacturer, to Launch Global Brand Campaign Targeting Millennial Generation Boat Users21.9.2017 14:30Pressemelding

On September 21, 2017, Tohatsu Corporation (headquartered in Tokyo, Japan; hereinafter &quot;TOHATSU&quot;) announced the outline of its global brand campaign at the 57th Genoa International Boat Show held in Genova, Italy. TOHATSU’s global brand campaign based on a new branding strategy will be deployed at boat shows around the world, starting from the Genoa International Boat Show in September 2017. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005018/en/ Feel the Wind (Photo: Business Wire) The campaign sets “SMARTS” millennials as its core target, revealing TOHATSU’s new brand logo, “Blue Wings” and its unique “Simpliq™ Technology” The feature of the new branding strategy is its target demographic called “SMARTS”, millennial boat owners (born between 1977 and 199

Sigma Systems Chief Technology Officer to Address CSPs at Futurecom 201721.9.2017 14:00Pressemelding

Sigma Systems, the global leader in catalog-driven software, has today announced that its Chief Technology Officer, Catherine Michel, will be speaking at Futurecom 2017 – the largest ICT event in Latin America. Catherine will address communications service providers (CSPs) and industry professionals at the Sao Paulo event on what’s driving the digitalization mandate for operators. Ahead of her presentation, Catherine commented: “The digitalization of the CSP is about transforming business operations, based on a thorough understanding of customer needs, behaviours and experiences. This requires a shift in corporate culture, and many CSPs are not making the changes necessary to embrace digital innovation and become market leading digital service providers. To deliver on a digital transformation, operators must embrace digital innovation and enable the rapid launch a

Encanto Potash Corp Secures CAD $100 Million Capital Commitment from GEM Global21.9.2017 13:00Pressemelding

Encanto Potash Corp. (&quot;Encanto&quot; or the &quot;Company&quot;) the TSX-V listed Potash development; Mining and Operating company (TSX-V: EPO) is pleased to announce that it has secured a commitment for a CAD $100 million funding facility. Under the funding agreement signed 15th September, 2017 (the &quot;Agreement&quot;), GEM Investments America, LLC and GEM Global Yield LLC SCS undertake to invest up to CAD $100,000,000 over the next three years. The proceeds will be used to commence the engineering and design phase of the mine in anticipation of a shovel-ready construction date of September 2019. Under a joint venture agreement with Muskowekwan Resources Ltd and Chief Reginald Bellerose of the First Nation’s Muskowekwan tribe, Encanto has secured the mineral rights for the mine and completed preliminary studies. In the interim, proceeds will also be used for the procurement an

CyberOptics Launches Coordinate Measurement Software Suite for New High Speed SQ3000™ CMM System21.9.2017 12:45Pressemelding

CyberOptics Corporation (Nasdaq: CYBE), a leading global developer and manufacturer of high-precision 3D sensing technology solutions, launches new SQ3000™ 3D CMM (Coordinate Measurement) system, powered by Multi-Reflection Suppression (MRS) technology and CyberCMM™, a new comprehensive software suite for coordinate measurement. In a lab or production environment, the SQ3000 CMM system is fast and highly accurate, with repeatable and reproducible measurements for metrology applications in manufacturing of a wide variety of products such as PCBs, semiconductors and consumer electronics. CyberOptics’ break-through MRS technology can be utilized for 3D automated optical inspection (AOI), and both 3D automated optical measurement (AOM) and 3D coordinate measurement (CMM) – far beyond a pass or fail inspection result. “We’re pairing our proprietary MRS sensor te

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom